A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19 : the Donated Antibodies Working against nCoV (DAWn-Plasma) trial (vol 21, 981, 2020)
- Author
- Timothy Devos, Tatjana Geukens, Alexander Schauwvlieghe (UGent) , Kevin K. Arien, Cyril Barbezange, Myriam Cleeren, Veerle Compernolle, Nicolas Dauby, Daniel Desmecht, David Grimaldi, Bart N. Lambrecht, Anne Luyten, Piet Maes, Michel Moutschen, Marta Romano, Lucie Seyler, Michel Toungouz Nevessignsky, Katleen Vandenberghe, Johan van Griensven, Geert Verbeke, Erika Vlieghe, Jean Cyr Yombi, Laurens Liesenborghs, Peter Verhamme and Geert Meyfroidt
- Organization
Downloads
-
s13063-020-04876-0.pdf
- full text (Corrected version)
- |
- open access
- |
- |
- 738.48 KB
-
s13063-020-04947-2.pdf
- full text (Corrected version)
- |
- open access
- |
- |
- 193.66 KB
Citation
Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-8693626
- MLA
- Devos, Timothy, et al. “A Randomized, Multicentre, Open-Label Phase II Proof-of-Concept Trial Investigating the Clinical Efficacy and Safety of the Addition of Convalescent Plasma to the Standard of Care in Patients Hospitalized with COVID-19 : The Donated Antibodies Working against NCoV (DAWn-Plasma) Trial (Vol 21, 981, 2020).” TRIALS, vol. 21, no. 1, 2020, doi:10.1186/s13063-020-04947-2.
- APA
- Devos, T., Geukens, T., Schauwvlieghe, A., Arien, K. K., Barbezange, C., Cleeren, M., … Meyfroidt, G. (2020). A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19 : the Donated Antibodies Working against nCoV (DAWn-Plasma) trial (vol 21, 981, 2020). TRIALS. https://doi.org/10.1186/s13063-020-04947-2
- Chicago author-date
- Devos, Timothy, Tatjana Geukens, Alexander Schauwvlieghe, Kevin K. Arien, Cyril Barbezange, Myriam Cleeren, Veerle Compernolle, et al. 2020. “A Randomized, Multicentre, Open-Label Phase II Proof-of-Concept Trial Investigating the Clinical Efficacy and Safety of the Addition of Convalescent Plasma to the Standard of Care in Patients Hospitalized with COVID-19 : The Donated Antibodies Working against NCoV (DAWn-Plasma) Trial (Vol 21, 981, 2020).” TRIALS. https://doi.org/10.1186/s13063-020-04947-2.
- Chicago author-date (all authors)
- Devos, Timothy, Tatjana Geukens, Alexander Schauwvlieghe, Kevin K. Arien, Cyril Barbezange, Myriam Cleeren, Veerle Compernolle, Nicolas Dauby, Daniel Desmecht, David Grimaldi, Bart N. Lambrecht, Anne Luyten, Piet Maes, Michel Moutschen, Marta Romano, Lucie Seyler, Michel Toungouz Nevessignsky, Katleen Vandenberghe, Johan van Griensven, Geert Verbeke, Erika Vlieghe, Jean Cyr Yombi, Laurens Liesenborghs, Peter Verhamme, and Geert Meyfroidt. 2020. “A Randomized, Multicentre, Open-Label Phase II Proof-of-Concept Trial Investigating the Clinical Efficacy and Safety of the Addition of Convalescent Plasma to the Standard of Care in Patients Hospitalized with COVID-19 : The Donated Antibodies Working against NCoV (DAWn-Plasma) Trial (Vol 21, 981, 2020).” TRIALS. doi:10.1186/s13063-020-04947-2.
- Vancouver
- 1.Devos T, Geukens T, Schauwvlieghe A, Arien KK, Barbezange C, Cleeren M, et al. A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19 : the Donated Antibodies Working against nCoV (DAWn-Plasma) trial (vol 21, 981, 2020). Vol. 21, TRIALS. 2020.
- IEEE
- [1]T. Devos et al., “A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19 : the Donated Antibodies Working against nCoV (DAWn-Plasma) trial (vol 21, 981, 2020),” TRIALS, vol. 21, no. 1. 2020.
@misc{8693626,
articleno = {1024},
author = {Devos, Timothy and Geukens, Tatjana and Schauwvlieghe, Alexander and Arien, Kevin K. and Barbezange, Cyril and Cleeren, Myriam and Compernolle, Veerle and Dauby, Nicolas and Desmecht, Daniel and Grimaldi, David and Lambrecht, Bart N. and Luyten, Anne and Maes, Piet and Moutschen, Michel and Romano, Marta and Seyler, Lucie and Nevessignsky, Michel Toungouz and Vandenberghe, Katleen and van Griensven, Johan and Verbeke, Geert and Vlieghe, Erika and Yombi, Jean Cyr and Liesenborghs, Laurens and Verhamme, Peter and Meyfroidt, Geert},
issn = {1745-6215},
language = {eng},
number = {1},
pages = {1},
series = {TRIALS},
title = {A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19 : the Donated Antibodies Working against nCoV (DAWn-Plasma) trial (vol 21, 981, 2020)},
url = {http://dx.doi.org/10.1186/s13063-020-04947-2},
volume = {21},
year = {2020},
}
- Altmetric
- View in Altmetric
- Web of Science
- Times cited: